Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.
Year: 2006
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: Yale Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, Henry Ford Health, Henry Ford Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Iowa, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center, American Health Network, City Of Hope National Medical Center, Vanderbilt-Ingram Cancer Center, Tufts Medical Center, Ligand Pharmaceuticals (United States)
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2980100627